# Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate

> **NCT00327990** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 300 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Ibandronate
- **DRUG:** Alendronate

## Key facts

- **NCT ID:** NCT00327990
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327990, "Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00327990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*